Episode Details

BWX Technologies, Inc. (BWXT) Q2 2026 — Reported after the close on August 3 (three months ended June 30, 2026). Revenue $901.6M, +18.0%. GAAP EPS $0.97 vs $0.85; non-GAAP EPS $1.07 vs $1.02, ahead of the ~$1.04 expected. Adjusted EBITDA $155.5M, +6.6%. Record backlog $8.40B, +39.6%. Guidance raised four ways. BWXT also agreed to sell its medical business to Nordic Capital for up to $800M and closed the Precision Components Group deal on July 1. The stock closed at $173.79, already 27% below its April high. The number nobody read: Government Operations — naval nuclear propulsion, 67% of revenue and about 81% of segment earnings — grew 2.1%, and its segment operating income FELL 3.4%. The actual nuclear franchise went sideways and earned less than a year ago. Commercial delivered 92% of all the growth, at roughly half the margin, largely acquired — with backlog up just 1.3%. THE CALL: AVOID (3/5, A GREAT FRANCHISE AT A PRICE THAT ASSUMES A DECADE) — base-case value ~$105.0 vs ~$173.79 today. KEY METRICS: - THE CALL: AVOID 3/5 - fair value ~$105 vs the $173.79 close (-40%); Street average ~$235 (11 buy / 4 hold / 1 sell, 16 analysts), so we DIFFER on the rating and are more CAUTIOUS on the number. DCF GRID (bear/base/bull x 8/9/10%): $55-45-37, $106-85-70, $138-109-89 - not one of the nine cells reaches $173.79. Probability-weighted 25/50/25 gives $81 at 9% and $101 at 8%; we sit at $105, using the 8% rate a sole-source naval monopoly deserves. REVERSE DCF: at $173.79 EV is $17.3B, which at 8% with 3% terminal growth demands ~$867M of FCF starting now against $352M guided - at 10% annual growth BWXT does not get there until 2035. - THE UNDER-COVERED ANGLE - THE NUCLEAR FRANCHISE GREW 2%. Government Operations did $601.3M, +2.1%, while segment operating income FELL 3.4% to $105.7M and segment adjusted EBITDA fell 4.9% to $126.5M (margin 22.6% to 21.0%) - management cites larger positive contract adjustments in the prior-year quarter and weaker mix. Commercial contributed $126.4M of the $137.6M revenue increase (92% of all growth), rising 71.7% to $302.5M - but much of that is acquired (Kinectrics, then PCG from July 1) and Commercial BACKLOG is $1.600B vs $1.580B, up just 1.3%. - ALSO: THE BACKLOG HEADLINE IS A Q1 EVENT, AND THE MIX IS DILUTIVE. Total backlog $8.40B (+39.6%) is real, but Q2 BOOKINGS were $648.9M vs $1,640.5M a year ago (-60%) - a 0.72x book-to-bill, though YTD bookings of $2.90B are a healthy 1.65x. Government earns a 21.0% adjusted EBITDA margin vs Commercial's 11.9%, so the mix shift (Commercial 23% to 34% of revenue) cut consolidated margin from 19.1% to 17.2% even as Commercial's own margin ROSE 270bps; FY Commercial margin was guided DOWN to ~13%. Free cash flow fell 9.0% to $115.0M as capex rose 26.6% to $41.4M while GAAP net income rose 14%. Net debt $1.41B ($2,019.9M debt less $608.2M cash). What to watch: Bullish: Commercial adjusted EBITDA margin above 16%; book-to-bill back above 1.2x for two quarters with Commercial backlog growing; a named, funded microreactor or SMR contract. Then $140. Bearish: Government under 3% growth again, Commercial margin stuck at ~13%, or FCF missing the raised guide. Any two and we are nearer $85. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.